<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003170.pub4" GROUP_ID="EYES" ID="691600081612403795" MERGED_FROM="" MODIFIED="2014-09-03 19:28:23 +0100" MODIFIED_BY="Anupa Shah" REVIEW_NO="CHWI01" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2014-09-03 19:28:23 +0100" MODIFIED_BY="Anupa Shah">
<TITLE>Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment</TITLE>
<CONTACT MODIFIED="2014-09-03 19:28:23 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="11349" ROLE="AUTHOR"><FIRST_NAME>Charles</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Wilkinson</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>cwilkins@gbmc.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Greater Baltimore Medical Center</ORGANISATION><ADDRESS_1>6569 North Charles Street, #505</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21204</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 443 849 2196</PHONE_1><FAX_1>+1 443 849 2648</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-09-03 19:28:23 +0100" MODIFIED_BY="Anupa Shah"><PERSON ID="11349" ROLE="AUTHOR"><FIRST_NAME>Charles</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Wilkinson</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>cwilkins@gbmc.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Greater Baltimore Medical Center</ORGANISATION><ADDRESS_1>6569 North Charles Street, #505</ADDRESS_1><CITY>Baltimore</CITY><ZIP>21204</ZIP><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 443 849 2196</PHONE_1><FAX_1>+1 443 849 2648</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-04-28 16:36:51 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-09-03 19:26:19 +0100" MODIFIED_BY="Anupa  Shah">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-03 19:26:19 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="26" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>Issue 9, 2014: Electronic searches were updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-09-03 19:25:59 +0100" MODIFIED_BY="Anupa  Shah">
<DATE DAY="26" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>Issue 9, 2014: No new trials were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-28 19:32:37 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-04-28 19:32:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 3, 2012: No new trials were identified for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-04-28 19:32:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>Issue 3, 2012: Electronic searches were updated. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-02-03 03:00:56 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Issue 3 2009: update searches yielded no new trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-05 15:54:16 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="10" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-06-17 17:38:01 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Greater Baltimore Medical Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Johns Hopkins University</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-06-17 17:38:01 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-06-17 17:38:01 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Eye Institute, National Institutes of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Methodological support was provided by the Cochrane Eyes and Vision Group US Project, Grant 1 U01 EY020522</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-03 19:26:39 +0100" MODIFIED_BY="Anupa  Shah">
<SUMMARY MODIFIED="2014-09-03 19:26:39 +0100" MODIFIED_BY="Anupa  Shah">
<TITLE>Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-03 19:26:39 +0100" MODIFIED_BY="Anupa  Shah">
<P>
<B>Review question</B>
<BR/>We reviewed the evidence about whether treatment of retinal breaks (holes or tears in the retina) and retinal lattice degeneration (thinning and atrophy of retinal tissue) can prevent retinal detachment, a serious vision-threatening problem.</P>
<P>
<B>Background</B>
<BR/>The retina is composed of membraneous layers at the back of the eye. It is the part of the eye that converts visual images into information interpreted by the brain as vision. Sometimes, retinal tissue can tear (known as retinal breaks). The effects of the tearing may cause visual disturbances such as dark floaters or flashing lights. When retinal breaks develop without symptoms, they are termed asymptomatic. Retinal lattice degeneration is a condition associated with retinal breaks in which the retinal tissue breaks down or thins in a lattice pattern.</P>
<P>When a retinal break occurs, fluid from the eye may leak between layers of the retina, specifically between the sensory retina and the retinal pigment epithelium, and cause separation. This separation is known as retinal detachment. Because retinal breaks and lattice degeneration are associated with retinal detachment, treatment of these conditions has been proposed as a way to prevent retinal detachment. Laser therapy or cryotherapy (freezing), or both, are often used with the goal of eliminating the fluid and space between retinal layers.</P>
<P>
<B>Results</B>
<BR/>The author of this review discovered no relevant studies. There is no evidence to demonstrate the effectiveness of prophylactic therapy for asymptomatic tears or holes in the retina. The evidence is current to February 2014.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-08-26 17:04:00 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-07-15 18:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>Asymptomatic retinal breaks and lattice degeneration are visible lesions that are risk factors for later retinal detachment. Retinal detachments occur when fluid in the vitreous cavity passes through tears or holes in the retina and separates the retina from the underlying retinal pigment epithelium. Creation of an adhesion surrounding retinal breaks and lattice degeneration, with laser photocoagulation or cryotherapy, has been recommended as an effective means of preventing retinal detachment. This therapy is of value in the management of retinal tears associated with the symptoms of flashes and floaters and persistent vitreous traction upon the retina in the region of the retinal break, because such symptomatic retinal tears are associated with a high rate of progression to retinal detachment. Retinal tears and holes unassociated with acute symptoms and lattice degeneration are significantly less likely to be the sites of retinal breaks that are responsible for later retinal detachment. Nevertheless, treatment of these lesions frequently is recommended, in spite of the fact that the effectiveness of this therapy is unproven.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-08-26 16:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to assess the effectiveness and safety of techniques used to treat asymptomatic retinal breaks and lattice degeneration for the prevention of retinal detachment.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-30 10:44:52 +0100" MODIFIED_BY=" Iris Gordon">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February 2014), EMBASE (January 1980 to February 2014), PubMed (January 1948 to February 2014), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 19 February 2014. Textbooks regarding retinal detachment and the reference lists of relevant reports were reviewed for additional study reports. We contacted experts in the field for details of other published and unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-08-19 02:22:38 +0100" MODIFIED_BY="[Empty name]">
<P>This review was designed to include randomized controlled trials in which one treatment for asymptomatic retinal breaks and lattice degeneration was compared with another treatment or no treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-08-19 01:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Initially, one author assessed the search results and collected relevant studies. Since no studies met the inclusion criteria, no studies were assessed for risk of bias. No data were extracted and no meta-analysis could be performed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No trials were found that met the inclusion criteria for this review. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-08-26 17:03:28 +0100" MODIFIED_BY="[Empty name]">
<P>No conclusions could be reached about the effectiveness of surgical interventions to prevent retinal detachment in eyes with asymptomatic retinal breaks or lattice degeneration, or both. Current recommendations for treatment, based upon a consensus of expert opinion, should be assessed in a randomized controlled trial.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-08-26 18:50:33 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-08-26 17:08:41 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-08-26 17:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>A retinal detachment is a separation of the sensory retina from the retinal pigment epithelium, with an accumulation of fluid in the potential space between them. Retinal detachments can be rhegmatogenous (caused by a break in the retina) or non-rhegmatogenous (caused by leakage from beneath the retina or by traction (pulling) on the retina). This review is concerned with the prophylactic treatment of the asymptomatic retinal breaks and areas of degeneration that might cause rhegmatogenous retinal detachment. Other Cochrane systematic reviews evaluating surgical treatments for rhegmatogenous retinal detachments are in preparation (<LINK REF="REF-Ramchand-2010" TYPE="REFERENCE">Ramchand 2010</LINK>; <LINK REF="REF-Znaor-2012" TYPE="REFERENCE">Znaor 2012</LINK>).</P>
<P>A break in the retina can be categorized as a tear or a hole. The break may be associated with symptoms or may be asymptomatic. Acute retinal breaks associated with the sudden onset of symptoms of dark floaters or flashing lights, or both, are a common cause of retinal detachment. Asymptomatic retinal breaks are much more common but much less likely to lead to retinal detachment. Therefore most retinal breaks do not lead to retinal detachment.</P>
<P>Lattice degeneration is a vitreoretinal disorder characterized by focal lesions which are associated with asymptomatic retinal holes and an increased likelihood of future retinal tears. Because asymptomatic retinal breaks and lattice degeneration are visible, common, and associated with retinal detachment, they have frequently been considered for prophylactic therapy.</P>
<P>Non-traumatic, phakic retinal detachments occur in approximately 1/10,000 persons/year (<LINK REF="REF-Haimann-1982" TYPE="REFERENCE">Haimann 1982</LINK>; <LINK REF="REF-Wilkes-1982" TYPE="REFERENCE">Wilkes 1982</LINK>). The incidence is slightly greater if traumatic cases are included, but approximately 1% to 2% of patients who undergo cataract surgery will ultimately develop a retinal detachment (<LINK REF="REF-Rowe-1999" TYPE="REFERENCE">Rowe 1999</LINK>; <LINK REF="REF-Tielsch-1996" TYPE="REFERENCE">Tielsch 1996</LINK>). Myopia is a major risk factor for retinal detachment, and there is a direct relationship between the amount of myopia and the chances of detachment (<LINK REF="REF-EDCSG-1993" TYPE="REFERENCE">EDCSG 1993</LINK>). The chances of retinal detachment are greater in the second eye of a person who has had a retinal detachment in one eye (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>).</P>
<P>Lattice degeneration is present in 6% to 8% of the general population and in approximately 30% of phakic retinal detachments (<LINK REF="REF-Byer-1992" TYPE="REFERENCE">Byer 1992</LINK>). The chances of a retinal detachment developing in an eye with lattice degeneration were less than 1% over an average of 11 years if retinal detachment had not occurred in the other eye (<LINK REF="REF-Byer-1989" TYPE="REFERENCE">Byer 1989</LINK>). In people with lattice degeneration in both eyes and a history of detachment in the first eye, the incidence of detachment in the second eye over seven years was between 2% to 5% (<LINK REF="REF-Folk-1989" TYPE="REFERENCE">Folk 1989</LINK>).</P>
<P>Asymptomatic retinal breaks are present in approximately 6% of eyes in both clinical and autopsy studies (<LINK REF="REF-Wilkinson-1997" TYPE="REFERENCE">Wilkinson 1997</LINK>). The chances of retinal detachment due to an asymptomatic retinal break in people in which a retinal detachment has not occurred in either eye were approximately 0.5% over a follow-up period averaging 11 years (<LINK REF="REF-Byer-1998" TYPE="REFERENCE">Byer 1998</LINK>). If a retinal detachment has occurred in one eye of a person with an asymptomatic retinal break in the second eye, the chances of retinal detachment in the latter eye appear to be higher, with incidence figures ranging from 0% to 15% (<LINK REF="REF-Wilkinson-1997" TYPE="REFERENCE">Wilkinson 1997</LINK>). However, data regarding such cases are incomplete, and the relationship between the asymptomatic breaks, new retinal breaks, and retinal detachment remains unclear.</P>
<P>Asymptomatic retinal breaks frequently are observed within the lesions of lattice degeneration. These are usually small atrophic holes; retinal detachments due to these breaks are usually slowly progressive and are most frequent in myopic eyes of patients less than 60 years of age.<BR/>
<B>
<BR/>
</B>Asymptomatic retinal breaks and lattice degeneration are usually diagnosed during routine evaluations of the peripheral retina following dilatation of the pupil. The lesions are usually present at the equator of the retina or more anteriorly, and the technique of scleral depression may be required for pathology to be visualized.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-08-19 01:30:43 +0100" MODIFIED_BY="[Empty name]">
<P>Asymptomatic retinal breaks and lattice degeneration are usually treated with transconjunctival cryotherapy or laser photocoagulation, or both. With cryotherapy, a probe shaped like a pen whose tip is cooled to very low temperatures is applied on the conjunctiva to freeze the retina through the outer layers of the eyeball. With laser photocoagulation, a high-energy beam is delivered through the ocular media to the affected area.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-08-26 17:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>With either technique, a thermal burn is created to surround the lesion and any subretinal fluid associated with it. The burn becomes an adhesion between the retina and retinal pigment epithelium to limit potential flow of fluid from the vitreous cavity through an asymptomatic break, retinal hole associated with lattice degeneration, or retinal break that occurs later at a site of lattice degeneration.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-08-19 02:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>An evidence-based approach to the practice of medicine has become more important in the face of increasing pressures to maintain quality care in the context of significant cost containment. In making a decision to treat vitreoretinal lesions that are relatively unlikely to cause retinal detachment, the risks that treatment will be unnecessary, ineffective, or even harmful must be weighed against the possible benefit of reducing the rate of subsequent retinal detachment. Therefore, a systematic review of the literature is indicated in an effort to evaluate the effectiveness of prophylactic therapy of asymptomatic retinal breaks and lattice degeneration.</P>
<P>This Cochrane review was preceded by a review of the literature for the production of an updated American Academy of Ophthalmology Preferred Practice Pattern (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>; <LINK REF="REF-Wilkinson-2000" TYPE="REFERENCE">Wilkinson 2000</LINK>). For this Cochrane review, the searches have been extended to include articles from non-English literature and to concentrate on the discovery of randomized controlled trials. The current review is the updated version of previously published Cochrane reviews (<LINK REF="REF-Wilkinson-2001" TYPE="REFERENCE">Wilkinson 2001</LINK>; <LINK REF="REF-Wilkinson-2005" TYPE="REFERENCE">Wilkinson 2005</LINK>; <LINK REF="REF-Wilkinson-2012" TYPE="REFERENCE">Wilkinson 2012</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-07-28 17:56:34 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to assess the effectiveness and safety of techniques used to treat asymptomatic retinal breaks and lattice degeneration for the prevention of retinal detachment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-08-26 18:50:19 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-08-26 18:50:10 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-08-19 02:22:27 +0100" MODIFIED_BY="[Empty name]">
<P>This review included randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-19 02:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>Trials included in this review included people with asymptomatic retinal breaks and lattice degeneration. These were divided into:</P>
<UL>
<LI>those in whom no retinal detachments had occurred; and</LI>
<LI>those in whom a retinal detachment had occurred in one eye and asymptomatic breaks or lattice degeneration, or both, were present in the second (fellow) eye.</LI>
</UL>
<P>Trials in which participants had acute symptoms of floaters and flashes were not included in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-08-26 17:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were included in which one treatment of asymptomatic retinal breaks and lattice degeneration was compared to control or to another form of treatment. Treatments included transconjunctival cryotherapy and laser photocoagulation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-08-26 18:50:10 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-26 18:50:10 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome for comparison of the treatments was the rate of retinal detachment following the intervention at one year after randomization. Retinal detachment was defined using a clinical diagnosis of retinal tear or retinal detachment as specified by included studies. Additional time points of interest for this outcome included six months, two years, and other time points as specified by the included studies.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-08-26 17:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary outcomes for comparison of the treatments included changes in visual acuity and socioeconomic implications (cost of intervention, morbidity). Loss of visual acuity was defined as a loss of 15 letters or more of visual acuity on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart.</P>
<P>We also included morbidity, reported by patients or by quality of life instruments (such as VQF-25), as data were available in individual studies. Morbidity due to retinal detachment is significant. Although approximately 95% of cases can be repaired successfully, a majority of these patients lose optimal visual acuity. Loss of visual acuity can lead to a loss of depth perception and difficulties with many tasks. The small percentage of treatment failures can lead to blindness and its expected morbidity.</P>
<P>We planned to report secondary outcomes measured at six months, one year, two years, and other time points reported by individual studies.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-08-26 17:20:39 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-08-26 17:20:39 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Eyes and Vision Group (CEVG) searched CENTRAL (which contains the CEVG Trials Register) (2014, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February 2014), EMBASE (January 1980 to February 2014), PubMed (January 1948 to February 2014), the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>). No date or language restrictions were used in the electronic searches for trials. The electronic databases were last searched on 19 February 2014.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), PubMed (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), <I>m</I>RCT (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), ClinicalTrials.gov (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) and the ICTRP (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-08-19 02:52:03 +0100" MODIFIED_BY="[Empty name]">
<P>For the original American Academy of Ophthalmology report (<LINK REF="REF-AAO-1998" TYPE="REFERENCE">AAO 1998</LINK>), experts in the field were contacted for information on further published and unpublished trials. These experts consisted of members of the American Academy of Ophthalmology Preferred Practice Pattern Retina Panel (including Dennis M. Robertson MD, Michael A. Bloome MD, Emily Y. Chew MD, Louis A. Lobes Jr. MD, David W. Parke II MD, Marco A. Zarbin MD, PhD, Paul P. Lee MD, JD, and Flora Lum MD). In the more recent Academy report (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>), a similar process was conducted by a different panel (composed of Emily Y. Chew MD, William E. Benson MD, H. Culver Boldt MD, Tom S. Chang MD, Louis A. Lobes MD, Joan W. Miller MD, Timothy G. Murray MD, Marco A. Zarbin MD, PhD, and Leslie Hyman PhD).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-08-26 18:50:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-08-26 17:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>The review author reviewed the titles and the abstracts of all the records identified through the electronic searches. The author assessed records for eligibility and classified each record as 'definitely relevant', 'possibly relevant', or 'definitely not relevant'. The full-text reports were obtained for records assessed as 'definitely relevant' or 'possibly relevant'. The author then assessed the full-text reports and judged whether each report was from a study that met the inclusion criteria. Studies excluded after full-text assessment were documented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table with reasons for exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-08-26 17:23:35 +0100" MODIFIED_BY="[Empty name]">
<P>If studies had met the inclusion criteria, data extraction forms developed by the Cochrane Eyes and Vision Group would have been used to record data related to study characteristics, characteristics of participants, interventions and comparisons, and outcomes prespecified in the Methods section. All data would have been entered into Review Manager (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). For any missing or unclear information, study investigators would have been contacted; after two weeks, if no response was received, the data would be used as available.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-08-26 17:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of sources of systematic bias was planned according to the guidelines in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The following five parameters were to be considered.</P>
<OL>
<LI>Sequence generation and allocation concealment.</LI>
<LI>Masking (blinding) of providers, recipients of care, and outcome assessors.</LI>
<LI>Incomplete outcome data.</LI>
<LI>Selective outcome reporting.</LI>
<LI>Other sources of bias.</LI>
</OL>
<P>Each parameter of trial quality was to be reported as 'low risk of bias', 'high risk of bias', or 'unclear risk of bias' (insufficient information to assess). For any missing or unclear information, study investigators would have been contacted; after two weeks, if no response was received, the data would be used as available.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-08-26 17:25:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous outcomes</HEADING>
<P>When data become available, the primary outcome (rate of retinal detachment) will be analyzed as a dichotomous outcome and the estimates of treatment effect expressed as risk ratios (RRs) with 95% confidence intervals (CIs). Change in visual acuity also may be treated as a dichotomous outcome, e.g., loss of 3 or more lines from baseline, as data are available in individual studies. Adverse events typically will be treated as dichotomous outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous outcomes</HEADING>
<P>Change in visual acuity may be treated as a continuous outcome, as data are available in individual studies. The treatment effect will be expressed as a mean difference (MD) with 95% CIs.</P>
<P>Cost of interventions, quality-of-life scores, and morbidity scales (e.g., discomfort, inflammation, and change in refractive error) also may be treated as continuous outcomes as data are available.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-08-26 18:01:08 +0100" MODIFIED_BY="[Empty name]">
<P>In future updates of this review, the unit of analysis will be the eye (one eye per participant).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-08-26 18:02:41 +0100" MODIFIED_BY="[Empty name]">
<P>As there is no eligible study in this review, no missing data was encountered. In the future, trial investigators will be contacted when desired data are missing or unclear. If investigators do not respond within two weeks, the data as available from the published report will be used (no data will be imputed).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-08-26 18:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>Since no studies were included, no assessment of heterogeneity was performed. If a sufficient number of studies are included in future updates of this review, clinical and methodological heterogeneity will be assessed by examining potential variations in study design, participants' characteristics, inclusion/exclusion criteria, interventions/comparisons, and primary and secondary outcomes. The proportion of variability across the included studies not due to chance will be quantified using the I<SUP>2 </SUP>statistic, with an I<SUP>2 </SUP>greater than 50% indicating substantial statistical heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-08-26 18:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>For selective outcome reporting, the outcomes prespecified in protocols or clinical trial registration will be compared with the outcomes in the published report(s) of included studies. The outcomes specified in the Methods section will be compared with the outcomes reported in the Results section in included trials when no protocol or clinical trial registration is available. To assess publication bias when ten or more studies are included in a meta-analysis, the symmetry of a funnel plot will be examined. Study characteristics and other factors that may contribute to asymmetry of the funnel plot also will be examined.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-08-26 18:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>Meta-analysis was planned to combine the results from included trials when clinical and methodological heterogeneity was assessed as minimal. If substantial heterogeneity was assessed, no meta-analysis was planned, rather results would be provided in a narrative summary. If future updates include fewer than three studies, fixed-effect model will be used; otherwise the random-effects model will be used for analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-08-26 18:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>Planned subgroup analysis included separate analysis of eyes with and without a history of retinal detachment in the other eye.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-08-26 18:42:51 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was not conducted due to no studies being included. Planned sensitivity analysis aimed to determine the impact of excluding studies with unclear or high risk of bias due to failure to conceal the allocation before randomization and high risk of reporting bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-08-19 04:48:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-08-19 04:48:17 +0100" MODIFIED_BY="[Empty name]">
<P>The original searches in 2001 found 154 citations but all were excluded by the author as none of them met the inclusion criteria.</P>
<P>
<I>Updated searches<BR/>
</I>In February 2005, the electronic searches were re-run and the author plus a member of the Cochrane Eyes and Vision Group screened the titles and abstracts of 160 citations. Four studies were found to be relevant to this review but none fulfilled the criteria for inclusion in this review. The excluded studies are mentioned in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>In November 2006, the electronic searches were re-run; 26 new reports of trials were identified but none met the inclusion criteria.</P>
<P>In November 2008, the electronic searches were updated and 23 new reports were identified. One study was found to be relevant to this review, but did not fulfill the criteria for inclusion (<LINK REF="STD-Ang-2008" TYPE="STUDY">Ang 2008</LINK>).</P>
<P>In January 2012, the electronic searches identified 34 citations along with eight potentially relevant ongoing or completed studies, but none met the inclusion criteria.</P>
<P>In February 2014, the electronic searches identified a total of 264 records (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After de-duplication of the results we screened 107 records, however none met the inclusion criteria.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-08-19 04:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>No studies met the criteria for inclusion in this review; therefore no assessment of quality was undertaken.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-08-19 04:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>There were no studies that met the inclusion criteria for this review; therefore no narrative summary or meta-analysis was performed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-08-26 18:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>The review author has found no randomized controlled trial of interventions for asymptomatic retinal breaks and lattice degeneration to prevent retinal detachment for inclusion in this review. The most frequently cited reports demonstrated many flaws and described treatment outcomes that were not compared to an appropriate control group.</P>
<P>An initial review of the literature regarding prevention of retinal detachment was performed by members of the American Academy of Ophthalmology Preferred Practice Pattern Retina Panel (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>). An electronic review of MEDLINE articles and a manual review of references from relevant textbooks was performed. Each article was assigned a 'level' relevant to the strength of evidence. Level I indicated a properly conducted, well-designed randomized controlled trial (or meta-analysis of these). Level II included evidence from well-designed controlled trials without randomization, cohort or case-control analytic studies, or multiple time series with or without the intervention. Level III included evidence from descriptive studies, case reports and consensus reports of expert committees.</P>
<P>In the previous review process (<LINK REF="REF-AAO-1998" TYPE="REFERENCE">AAO 1998</LINK>), one retrospective analysis (<LINK REF="REF-Folk-1989" TYPE="REFERENCE">Folk 1989</LINK>) had been considered to constitute Level II evidence. However, in the more recent review (<LINK REF="REF-AAO-2003" TYPE="REFERENCE">AAO 2003</LINK>), these data were considered to provide insufficient evidence to guide management. This study evaluated a large number of eyes in which lattice degeneration was present in the fellow eye of people with a retinal detachment associated with lattice degeneration in the first eye. Although treated eyes were compared to a control series, the method of allocation to treatment or observation was unclear, and a treatment benefit in eyes at highest risk was not demonstrated.</P>
<P>Most reports regarding prophylactic therapy have discussed treatment of lesions believed to be associated with an increased risk of retinal tears and detachments. Although there are well-established risk factors associated with the development of retinal detachment, evidence of a benefit of prophylactic therapy in eyes without symptoms is lacking, and the risk of retinal detachment appears to persist in spite of preventive treatment.</P>
<P>The primary limitation of prophylactic therapy is related to the fact that most retinal detachments are due to retinal tears that develop in areas of the retina that appear normal prior to vitreous detachment (<LINK REF="REF-Byer-1992" TYPE="REFERENCE">Byer 1992</LINK>; <LINK REF="REF-Chauhan-2006" TYPE="REFERENCE">Chauhan 2006</LINK>). Thus treatment of visible lesions associated with retinal detachment may prevent a tear at those sites, but not a tear in normal appearing retina.</P>
<P>A major flaw in the vast majority of reports discussing prophylactic therapy was an absence of a discussion of the state of the vitreous gel before treatment. A prospective natural course trial of aphakic fellow eyes of patients who had had a prior retinal detachment in their first eye demonstrated that eyes without a posterior vitreous detachment had a tenfold higher chance of experiencing a later retinal detachment than did eyes in which a posterior vitreous detachment was present at the onset of the observation (<LINK REF="REF-Hovland-1978" TYPE="REFERENCE">Hovland 1978</LINK>). No known prospective or retrospective non-controlled treatment trials to date have been stratified for the presence or absence of a posterior vitreous detachment.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-08-26 17:01:55 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-19 04:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>There are no randomized controlled trials to support conclusions regarding the value of treating asymptomatic retinal breaks to prevent retinal detachment. A meaningful study likely would require long follow-up of a large number of treated and untreated patients with similar clinical characteristics because the expected rate of retinal detachment in both groups is low. Even in patients in which a detachment in the other eye has occurred, the rate of detachment in the untreated eyes may be less than 10% over five to seven years. Such a study would be both difficult and expensive.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-08-26 17:01:55 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomized trials of treatment for eyes with a relatively high risk of later detachment should offer the best opportunity to provide outcome data that are statistically meaningful. High-risk cases may include highly myopic fellow eyes with lattice degeneration and no posterior vitreous detachment, which are also pseudophakic or scheduled for cataract surgery. Such a prospective trial of treatment versus observation should include appropriate numbers of participants observed over a sufficiently long follow-up period to ensure that the questions regarding outcomes of therapy versus no therapy are answered in a satisfactory statistical fashion.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-06-17 17:34:07 +0100" MODIFIED_BY="[Empty name]">
<P>The review author acknowledges the invaluable assistance of Dennis M. Robertson MD, Emily Y. Chew MD and the additional members of the American Academy of Ophthalmology Preferred Practice Pattern Retina Panels. The electronic searches for this review were conducted by the Cochrane Eyes and Vision Group editorial team.</P>
<P>Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-19 04:38:42 +0100" MODIFIED_BY="[Empty name]">
<P>Charles P. Wilkinson (CPW) screened the search results, graded selected trials and wrote the review. CPW is the guarantor for the review.<BR/>The Cochrane Eyes and Vision Group (CEVG) editorial team developed the search strategies and undertook the electronic searches. The CEVG also provided methodological support, including review of titles/abstracts, and assessment of full-text records of potentially included studies, etc.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-08-26 18:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>The Methods section of this version of the review was updated to reflect the reporting and conduct standards for Cochrane reviews. Many methods planned for this review (e.g., data extraction, risk of bias assessment, meta-analysis) were not conducted because the review identified no eligible studies.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-08-19 03:02:07 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-07-30 11:35:14 +0100" MODIFIED_BY=" Iris Gordon">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2014-07-30 11:35:14 +0100" MODIFIED_BY=" Iris Gordon">
<STUDY DATA_SOURCE="PUB" ID="STD-Ang-2008" MODIFIED="2009-03-02 14:34:10 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ang 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-02 14:34:10 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ang A, Poulson AV, Goodburn SF, Richards AJ, Scott JD, Snead MP</AU>
<TI>Retinal detachment and prophylaxis in type 1 Stickler syndrome</TI>
<SO>Ophthalmology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>1</NO>
<PG>164-8</PG>
<IDENTIFIERS MODIFIED="2009-03-02 14:34:10 +0000" MODIFIED_BY=" Iris Gordon"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avitabile-2004" MODIFIED="2014-07-30 11:35:14 +0100" MODIFIED_BY=" Iris Gordon" NAME="Avitabile 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-07-30 11:35:14 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avitabile T, Bonfiglio V, Reibaldi M, Torrisi B, Reibaldi A</AU>
<TI>Prophylactic treatment of the fellow eye of patients with retinal detachment: A retrospective study</TI>
<SO>Graefes Archive for Clinical and Experimental Ophthalmology</SO>
<YR>2004</YR>
<VL>242</VL>
<NO>3</NO>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isola-2001" MODIFIED="2009-03-02 14:35:28 +0000" MODIFIED_BY=" Iris Gordon" NAME="Isola 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-02 14:35:28 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isola V, Spinelli G, Misefari W</AU>
<TI>Transpupillary retinopexy of chorioretinal lesions predisposing to retinal detachment with the use of diode (810 nm) microlaser</TI>
<SO>Retina</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>5</NO>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saracco-1980" MODIFIED="2009-03-02 14:38:05 +0000" MODIFIED_BY=" Iris Gordon" NAME="Saracco 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-03-02 14:38:05 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saracco JB, Estachy GM, Gastaud P, Maymard I</AU>
<TI>Prophylactic treatment of aphakic retinal detachment by argon laser photocoagulation. Study on 600 cases</TI>
<SO>Ophthalmologica</SO>
<YR>1980</YR>
<VL>181</VL>
<NO>3-4</NO>
<PG>142-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfensberger-2003" MODIFIED="2009-03-02 14:38:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wolfensberger 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-02 14:38:21 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfensberger TJ, Aylward GW, Leaver PK</AU>
<TI>Prophylactic 360 degrees cryotherapy in fellow eyes of patients with spontaneous giant retinal tears</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>6</NO>
<PG>1175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-08-19 03:02:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-30 10:57:29 +0100" MODIFIED_BY=" Iris Gordon">
<REFERENCE ID="REF-AAO-1998" NAME="AAO 1998" TYPE="BOOK">
<AU>American Academy of Ophthalmology</AU>
<SO>Preferred Practice Patterns: Management of posterior vitreous detachment, retinal breaks and lattice degeneration</SO>
<YR>1998</YR>
<PB>American Academy of Ophthalmology</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AAO-2003" NAME="AAO 2003" TYPE="BOOK">
<AU>American Academy of Ophthalmology</AU>
<SO>Preferred Practice Patterns: Management of posterior vitreous detachment, retinal breaks, and lattice degeneration</SO>
<YR>2003</YR>
<PG>1-20</PG>
<PB>American Academy of Ophthalmology</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Byer-1989" MODIFIED="2009-03-02 14:40:48 +0000" MODIFIED_BY=" Iris Gordon" NAME="Byer 1989" TYPE="JOURNAL_ARTICLE">
<AU>Byer NE</AU>
<TI>Long-term natural history of lattice degeneration of the retina</TI>
<SO>Ophthalmology</SO>
<YR>1989</YR>
<VL>96</VL>
<NO>9</NO>
<PG>1396-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Byer-1992" NAME="Byer 1992" TYPE="BOOK_SECTION">
<AU>Byer NE</AU>
<TI>Rethinking prophylactic therapy of retinal detachment</TI>
<SO>Advances in Vitreoretinal Surgery</SO>
<YR>1992</YR>
<PG>399-411</PG>
<ED>Stirpe M</ED>
<PB>Ophthalmic Communications Society</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Byer-1998" MODIFIED="2009-03-02 14:42:02 +0000" MODIFIED_BY=" Iris Gordon" NAME="Byer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Byer NE</AU>
<TI>What happens to untreated asymptomatic retinal breaks, and are they affected by posterior vitreous detachment?</TI>
<SO>Ophthalmology</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>6</NO>
<PG>1045-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chauhan-2006" MODIFIED="2009-03-02 14:43:05 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chauhan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chauhan DS, Downie JA, Eckstein M, Aylward GW</AU>
<TI>Failure of prophylactic retinopexy in fellow eyes without a posterior vitreous detachment</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2006</YR>
<VL>124</VL>
<NO>7</NO>
<PG>968-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EDCSG-1993" MODIFIED="2009-03-02 14:45:34 +0000" MODIFIED_BY=" Iris Gordon" NAME="EDCSG 1993" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Risk factors for idiopathic rhegmatogenous retinal detachment. The Eye Disease Case-Control Study Group</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1993</YR>
<VL>137</VL>
<NO>7</NO>
<PG>749-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folk-1989" MODIFIED="2009-03-02 14:46:09 +0000" MODIFIED_BY=" Iris Gordon" NAME="Folk 1989" TYPE="JOURNAL_ARTICLE">
<AU>Folk JC, Arrindell EL, Klugman MR</AU>
<TI>The fellow eye of patients with phakic lattice retinal detachment</TI>
<SO>Ophthalmology</SO>
<YR>1989</YR>
<VL>96</VL>
<NO>1</NO>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haimann-1982" NAME="Haimann 1982" TYPE="JOURNAL_ARTICLE">
<AU>Haimann MH, Burton TC, Brown CK</AU>
<TI>Epidemiology of retinal detachment</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1982</YR>
<VL>100</VL>
<NO>2</NO>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-02-03 03:05:24 +0000" MODIFIED_BY=" Iris Gordon" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hovland-1978" NAME="Hovland 1978" TYPE="JOURNAL_ARTICLE">
<AU>Hovland KR</AU>
<TI>Vitreous findings in fellow eyes of aphakic retinal detachment</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1978</YR>
<VL>86</VL>
<NO>3</NO>
<PG>350-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramchand-2010" MODIFIED="2014-07-30 10:57:29 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ramchand 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Ramchand K, Hatef E, Sena DF, Fallano KA, Do DV</AU>
<TI>Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-07-28 17:54:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-28 17:54:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008350"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-04-28 15:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan). 5.2</TI>
<YR>2012</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-1999" NAME="Rowe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rowe JA, Erie JC, Baratz KH, Hodge DO, Gray DT, Butterfield L, et al</AU>
<TI>Retinal detachment in Olmsted County, Minnesota, 1976 through 1995</TI>
<SO>Ophthalmology</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>1</NO>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tielsch-1996" NAME="Tielsch 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tielsch JM, Legro MW, Cassard SD, Schein OD, Javitt JC, Singer AE, et al</AU>
<TI>Risk factors for retinal detachment after cataract surgery. A population-based case-control study</TI>
<SO>Ophthalmology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>10</NO>
<PG>1537-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkes-1982" NAME="Wilkes 1982" TYPE="JOURNAL_ARTICLE">
<AU>Wilkes SR, Beard CM, Kurland LT, Robertson DM, O'Fallon WM</AU>
<TI>The incidence of retinal detachment in Rochester, Minnesota, 1970-1978</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>94</VL>
<NO>5</NO>
<PG>670-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-1997" NAME="Wilkinson 1997" TYPE="BOOK">
<AU>Wilkinson CP, Rice TA</AU>
<SO>Michels Retinal Detachment</SO>
<YR>1997</YR>
<PB>Mosby-Year Book</PB>
<CY>St Louis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Znaor-2012" MODIFIED="2014-07-28 17:55:24 +0100" MODIFIED_BY="[Empty name]" NAME="Znaor 2012" TYPE="COCHRANE_PROTOCOL">
<AU>Znaor L, Medic A, Marin J, Binder S, Lukic I, George J</AU>
<TI>Pars plana vitrectomy versus scleral buckle for repairing simple rhegmatogenous retinal detachments</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-07-28 17:55:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-28 17:55:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009562"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-08-19 03:02:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Wilkinson-1999" MODIFIED="2014-07-30 11:06:15 +0100" MODIFIED_BY=" Iris Gordon" NAME="Wilkinson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson CP</AU>
<TI>Evidence-based medicine regarding the prevention of retinal detachment</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1999</YR>
<VL>97</VL>
<PG>397-404</PG>
<IDENTIFIERS MODIFIED="2014-04-28 18:28:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2000" MODIFIED="2014-04-28 18:31:05 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson CP</AU>
<TI>Evidence-based analysis of prophylactic treatment of asymptomatic retinal breaks and lattice degeneration</TI>
<SO>Ophthalmology</SO>
<YR>2000</YR>
<VL>107</VL>
<NO>1</NO>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2001" MODIFIED="2014-05-14 17:55:46 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 2001" TYPE="COCHRANE_REVIEW">
<AU>Wilkinson C</AU>
<TI>Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-28 16:58:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-28 16:58:25 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003170"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2005" MODIFIED="2012-02-08 14:56:42 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wilkinson 2005" TYPE="COCHRANE_REVIEW">
<AU>Wilkinson CP</AU>
<TI>Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-02-08 14:56:42 +0000" MODIFIED_BY=" Iris Gordon">
<IDENTIFIER MODIFIED="2012-02-08 14:56:42 +0000" MODIFIED_BY=" Iris Gordon" TYPE="DOI" VALUE="10.1002/14651858.CD003170.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2006" MODIFIED="2014-08-19 03:02:07 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 2006" TYPE="BOOK_SECTION">
<AU>Wilkinson CP</AU>
<TI>Prevention of retinal detachment</TI>
<SO>Retina</SO>
<YR>2013</YR>
<VL>3</VL>
<PG>1793&#8211;1806</PG>
<EN>5th</EN>
<ED>Wilkinson CP, Wiedemann P, Ryan SJ</ED>
<PB>Elsevier Saunders</PB>
<IDENTIFIERS MODIFIED="2014-04-28 19:07:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2012" MODIFIED="2014-04-28 16:57:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 2012" TYPE="COCHRANE_REVIEW">
<AU>Wilkinson CP</AU>
<TI>Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-28 16:57:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-28 16:57:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003170.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-03-05 15:50:07 +0000" MODIFIED_BY="Anupa Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-03-05 15:50:07 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-03-05 15:50:07 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Ang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-05 15:50:07 +0000" MODIFIED_BY="Anupa Shah">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Avitabile-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared intervention group with historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Isola-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saracco-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolfensberger-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-07-31 15:40:48 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-07-31 15:40:48 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Results from searching for studies for inclusion in the review </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmIAAAGZCAYAAAAq612hAAA8rklEQVR42u2df2RX7R//P+SWJInk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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-30 10:47:10 +0100" MODIFIED_BY=" Iris Gordon">
<APPENDIX ID="APP-01" MODIFIED="2014-07-29 15:07:47 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-02 15:02:02 +0000" MODIFIED_BY=" Iris Gordon">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor: [Retinal Detachment] explode all trees<BR/>#2 MeSH descriptor: [Retinal Perforations] explode all trees<BR/>#3 MeSH descriptor: [Vitreous Detachment] explode all trees<BR/>#4 (retina* near/3 (detach* or break* or perforat* or tear* or hole*))<BR/>#5 vitreoretinal near/3 degenerat*<BR/>#6 vitreo retinal near/3 degenerat*<BR/>#7 lattice near/3 degenerat*<BR/>#8 vitreo* near/3 detach* near/3 posterior<BR/>#9 {or #1-#8}<BR/>#10 MeSH descriptor: [Light Coagulation] explode all trees<BR/>#11 MeSH descriptor: [Cryotherapy] explode all trees<BR/>#12 (coagulat* near/3 (light or lasers))<BR/>#13 laser* near/3 photocoagulat*<BR/>#14 laser* near/3 photo coagulat*<BR/>#15 cryotherap*<BR/>#16 {or #10-#15}<BR/>#17 prophyla*<BR/>#18 prevent*<BR/>#19 {or #17-#18}<BR/>#20 #9 and #16 and #19</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-07-30 10:47:10 +0100" MODIFIED_BY=" Iris Gordon" NO="2">
<TITLE MODIFIED="2014-07-30 10:47:10 +0100" MODIFIED_BY=" Iris Gordon">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:08:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Randomized Controlled Trial.pt.<BR/>2. Controlled Clinical Trial.pt.<BR/>3. (randomized or randomised).ab,ti.<BR/>4. placebo.ab,ti.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab,ti.<BR/>7. trial.ab,ti.<BR/>8. groups.ab,ti.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10<BR/>12. exp retinal detachment/<BR/>13. exp retinal perforations/<BR/>14. exp vitreous detachment/<BR/>15. (retina$ adj3 (detach$ or break$ or perforat$ or tear$ or hole$)).tw.<BR/>16. (vitreoretinal adj3 degenerat$).tw.<BR/>17. (vitreo retinal adj3 degenerat$).tw.<BR/>18. (lattice adj3 degenerat$).tw.<BR/>19. (vitreo$ adj3 detach$ adj3 posterior).tw.<BR/>20. or/12-19<BR/>21. exp light coagulation/<BR/>22. exp cryotherapy/<BR/>23. (coagulat$ adj3 (light or laser$)).tw.<BR/>24. (laser$ adj3 photocoagulat$).tw.<BR/>25. (laser$ adj3 photo coagulat$).tw.<BR/>26. cryotherap$.tw.<BR/>27. or/21-26<BR/>28. prophyla$.tw.<BR/>29. prevent$.tw.<BR/>30. or/28-29<BR/>31. 20 and 27 and 30<BR/>32. 11 and 31</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy was from the published paper by Glanville et al (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-29 15:16:53 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-29 15:16:53 +0100" MODIFIED_BY="[Empty name]">EMBASE.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>#1 'randomized controlled trial'/exp<BR/>#2 'randomization'/exp<BR/>#3 'double blind procedure'/exp<BR/>#4 'single blind procedure'/exp<BR/>#5 random*:ab,ti<BR/>#6 #1 OR #2 OR #3 OR #4 OR #5<BR/>#7 'animal'/exp OR 'animal experiment'/exp<BR/>#8 'human'/exp<BR/>#9 #7 AND #8<BR/>#10 #7 NOT #9<BR/>#11 #6 NOT #10<BR/>#12 'clinical trial'/exp<BR/>#13 (clin* NEAR/3 trial*):ab,ti<BR/>#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti<BR/>#15 'placebo'/exp<BR/>#16 placebo*:ab,ti<BR/>#17 random*:ab,ti<BR/>#18 'experimental design'/exp<BR/>#19 'crossover procedure'/exp<BR/>#20 'control group'/exp<BR/>#21 'latin square design'/exp<BR/>#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21<BR/>#23 #22 NOT #10<BR/>#24 #23 NOT #11<BR/>#25 'comparative study'/exp<BR/>#26 'evaluation'/exp<BR/>#27 'prospective study'/exp<BR/>#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti<BR/>#29 #25 OR #26 OR #27 OR #28<BR/>#30 #29 NOT #10<BR/>#31 #30 NOT (#11 OR #23)<BR/>#32 #11 OR #24 OR #31<BR/>#33 'retina detachment'/exp<BR/>#34 'vitreoretinal degeneration'/exp<BR/>#35 (retina* NEAR/3 (detach* OR break* OR perforat* OR tear* OR hole*)):ab,ti<BR/>#36 (vitreoretinal NEAR/3 degenerat*):ab,ti<BR/>#37 ('vitreo retinal' NEAR/3 degenerat*):ab,ti<BR/>#38 (lattice NEAR/3 degenerat*):ab,ti<BR/>#39 #33 OR #34 OR #35 OR #36 OR #37 OR #38<BR/>#40 'laser coagulation'/exp<BR/>#41 'cryotherapy'/exp<BR/>#42 (coagulat* NEAR/3 (light OR laser*)):ab,ti<BR/>#43 (laser* NEAR/3 photocoagulat*):ab,ti OR (laser*:ab,ti AND (photo NEXT/1 coagulat*):ab,ti)<BR/>#44 cryotherap*:ab,ti<BR/>#45 #40 OR #41 OR #42 OR #43 OR #44<BR/>#46 'prophylaxis'/exp<BR/>#47 prophyla*:ab,ti<BR/>#48 prevent*:ab,ti<BR/>#49 #46 OR #47 OR #48<BR/>#50 #39 AND #45 AND #49<BR/>#51 #32 AND #50</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-29 15:20:05 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-07-29 15:19:52 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:20:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomised[tiab] OR randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT humans[mh])<BR/>2. (retina*[tw] AND (detach*[tw] or break*[tw] or perforat*[tw] or tear*[tw] or hole*[tw])) NOT Medline[sb]<BR/>3. (vitreoretinal[tw] AND degenerat*[tw]) NOT Medline[sb]<BR/>4. (vitreo retinal[tw] AND degenerat*[tw]) NOT Medline[sb]<BR/>5. (lattice[tw] AND degenerat*[tw]) NOT Medline[sb]<BR/>6. (vitreo*[tw] AND detach*[tw] AND posterior[tw]) NOT Medline[sb]<BR/>7. #2 OR #3 OR #4 OR #5 OR #6<BR/>8. (coagulat*[tw] AND (light[tw] or laser*[tw])) NOT Medline[sb]<BR/>9. (laser*[tw] AND photocoagulat*[tw]) NOT Medline[sb]<BR/>10. (laser*[tw] AND photo coagulat*[tw]) NOT Medline[sb]<BR/>11. cryotherap*[tw] NOT Medline[sb]<BR/>12. #8 OR #9 OR #10 OR #11<BR/>13. prophyla*[tw] NOT Medline[sb]<BR/>14. prevent*[tw] NOT Medline[sb]<BR/>15. #13 OR #14<BR/>16. #7 AND #12 AND #15<BR/>17. #1 AND #16</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-07-29 15:19:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-07-29 15:19:39 +0100" MODIFIED_BY="[Empty name]">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:19:26 +0100" MODIFIED_BY="[Empty name]">
<P>(prevention or prophylaxis or prophylatic) and retinal detachment</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-07-29 15:19:18 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-07-29 15:19:18 +0100" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>(Prevention OR Prophylaxis OR Prophylatic) AND Retinal Detachment</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2014-07-29 15:20:01 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2014-07-29 15:18:42 +0100" MODIFIED_BY="[Empty name]">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 15:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Prevention AND Retinal Detachment OR Prophylaxis AND Retinal Detachment OR Prophylatic AND Retinal Detachment</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies included in the updated version of the review&lt;/p&gt;" WIDTH="162">
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies included in previous versions of the review (searches as of January 2012)&lt;/p&gt;" WIDTH="154"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;107 records screened by the authors&lt;/p&gt;" WIDTH="190">
<FLOWCHARTBOX TEXT="&lt;p&gt;107 records after duplicates removed&lt;/p&gt;" WIDTH="185">
<FLOWCHARTBOX TEXT="&lt;p&gt;264 records identified through electronic database searching (January 2012 to February 2014)&lt;/p&gt;" WIDTH="181"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;107 records excluded as not relevant&lt;/p&gt;" WIDTH="146"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_11349_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="11349"><ADDRESS><DEPARTMENT>Department of Ophthalmology</DEPARTMENT><ORGANISATION>Johns Hopkins University</ORGANISATION><CITY>Baltimore</CITY><REGION>Maryland</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>